摘要
2019年12月以来,随着严重急性呼吸综合征冠状病毒2型(severe acute respiratory syndrome coronavirus 2,SARS-CoV-2)所致的疫情蔓延和对其认识的加深,药物治疗方案得到越来越多的关注,不断被改进更新。为了加强药学服务协助疫情防控,本文针对目前国家卫生健康委员会推荐的《新型冠状病毒肺炎诊疗方案(试行第六版)》抗病毒药α干扰素、洛匹那韦/利托那韦、利巴韦林、阿比多尔和磷酸氯喹,结合现有研究资料汇总合理使用具体注意点,供各医疗机构在新型冠状病毒肺炎(corona virus disease-19,COVID-19)诊疗中参考。
Since December 2019,with the spread and deepening awareness of COVID-19 caused by SARS-CoV-2,pharmaceutical treatment received more and more attention,and are constantly being improved and updated.In order to strengthen pharmaceutical services to assist in epidemic prevention and control,this article targets the currently recommended antiviral chemicals:interferon-α,lopinavir/ritonavir,ribavirin,abidol and chloroquine phosphate.There are specific attention points for reasonable use based on research data for reference in COVID-19 diagnosis and treatment.
作者
徐晓涵
翟所迪
杨丽
XU Xiaohan;ZHAI Suodi;YANG Li(Dept.of Pharmacy,Peking University Third Hospital,Beijing 100191,China)
出处
《中国医院用药评价与分析》
2020年第2期129-133,139,共6页
Evaluation and Analysis of Drug-use in Hospitals of China
